Lepu Biopharma Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
646
- Stock Symbol
-
02157
- Investments
-
6
- Share Price
-
$0.34
- (As of Friday Closing)
Lepu Biopharma General Information
Description
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
Contact Information
Website
www.lepubiopharma.comCorporate Office
- No.651, Lianheng Road
- Minhang District
- Shanghai, 201612
- China
Corporate Office
- No.651, Lianheng Road
- Minhang District
- Shanghai, 201612
- China
Lepu Biopharma Stock Performance
As of 13-Nov-2026, Lepu Biopharma’s stock price is $0.34. Its current market cap is $621M with 1.8B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.34 | $0.36 | $0.34 - $0.85 | $621M | 1.8B | 11.6M | $0.02 |
Lepu Biopharma Financials Summary
As of 30-Jun-2026, Lepu Biopharma has a trailing 12-month revenue of $142M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 906,784 | 1,208,391 | 600,674 | 921,153 |
| Revenue | 141,674 | 130,000 | 51,257 | 31,852 |
| EBITDA | 40,355 | 52,459 | (42,789) | 11,152 |
| Net Income | 35,301 | 36,344 | (57,331) | (3,123) |
| Total Assets | 465,929 | 443,021 | 312,418 | 336,358 |
| Total Debt | 173,746 | 152,048 | 116,459 | 105,355 |
Lepu Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lepu Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Lepu Biopharma Patents
Lepu Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026175405-A1 | Linker compounds and antibody-drug conjugates thereof, method for preparing same, and use thereof | Pending | 21-Feb-2025 | ||
| WO-2026124417-A1 | Anti-cdh17 antibody-drug conjugates and uses thereof | Pending | 09-Dec-2024 | ||
| WO-2026108970-A1 | Combination therapy for recurrent or metastatic nasopharyngeal carcinoma | Pending | 22-Nov-2024 | ||
| WO-2026082154-A1 | Anti-beta amyloid antibodies and uses thereof | Pending | 18-Oct-2024 | ||
| WO-2026037321-A1 | Compounds, compositions and methods | Pending | 13-Aug-2024 | A61P35/00 |
Lepu Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Lepu Biopharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lepu Biopharma Investments & Acquisitions (6)
Lepu Biopharma’s most recent deal was a Later Stage VC with Zenas BioPharma for . The deal was made on 03-May-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zenas BioPharma | 03-May-2024 | Later Stage VC | Drug Discovery | ||
| Miracogen | 01-May-2020 | Corporate | Drug Discovery | ||
| KYM Biosciences | 02-Dec-2019 | Joint Venture | Drug Discovery | ||
| HealSun Biopharm | 09-Aug-2018 | Corporate | Biotechnology | ||
| Binhui Biopharm | 03-Aug-2018 | Later Stage VC | Drug Discovery |
Lepu Biopharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.54 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Lepu Biopharma Exits (1)
Lepu Biopharma’s most recent exit was on 03-May-2024 from Zenas BioPharma. The exit was categorized as with 16 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Zenas BioPharma | 03-May-2024 | Completed |
|
Lepu Biopharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Miracogen | Shanghai, China | 2014 |
Lepu Biopharma FAQs
-
When was Lepu Biopharma founded?
Lepu Biopharma was founded in 2018.
-
Where is Lepu Biopharma headquartered?
Lepu Biopharma is headquartered in Shanghai, China.
-
What is the size of Lepu Biopharma?
Lepu Biopharma has 646 total employees.
-
What industry is Lepu Biopharma in?
Lepu Biopharma’s primary industry is Drug Discovery.
-
Is Lepu Biopharma a private or public company?
Lepu Biopharma is a Public company.
-
What is Lepu Biopharma’s stock symbol?
The ticker symbol for Lepu Biopharma is 02157.
-
What is the current stock price of Lepu Biopharma?
As of 13-Nov-2026 the stock price of Lepu Biopharma is $0.34.
-
What is the current market cap of Lepu Biopharma?
The current market capitalization of Lepu Biopharma is $621M.
-
What is Lepu Biopharma’s current revenue?
The trailing twelve month revenue for Lepu Biopharma is $142M.
-
What is Lepu Biopharma’s annual earnings per share (EPS)?
Lepu Biopharma’s EPS for 12 months was $0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
